 |
Richard KitchingAcademic Nephrologist-Scientist | Monash University and Monash HealthRichard Kitching is an academic nephrologist-scientist and NHMRC Investigator Fellow with a special interest in immune kidney disease, particularly ANCA-associated vasculitis. He holds Monash University and Monash Heath appointments and heads the Monash Vasculitis Clinic. In late 2018 he and colleagues in Australia and New Zealand from the disciplines of Clinical Immunology, Nephrology and Rheumatology founded the ANZ Vasculitis Society (ANZVASC), a patient facing multidisciplinary professional society to improve vasculitis education, research and care in Australia and New Zealand. With his ANZVASC colleagues, he established the ANZVASC Quality and Disease Registry in 2023. He is an Associate Editor for the J Am Soc Nephrol and serves on the Editorial Boards of, Kidney Int, Clin J Am Soc Nephrol. His fundamental and early translational research focusses on autoimmune kidney disease, from loss of tolerance to effector responses, aiming to use more targeted therapies and restore tolerance. His publications include papers in Nature, Nature Reviews Disease Primers, Nature Medicine, Nature Reviews Immunology, Nature Communications, J Am Soc Nephrol, Kidney Int, PNAS USA and the Journal of Clinical Investigation |
Presentation title: New options and challenges in the management of ANCA-associated vasculitis
With the publication of newer clinical trials, re-interpretation of previous trials, changes in the funding structure for rituximab (in Australia), complement inhibition, and the pandemic, new questions, opportunities and challenges have arisen in the management of ANCA-associated vasculitis (AAV). This presentation will focus on some of these issues including glucocorticoid dosing, rituximab and cyclophosphamide use, plasma exchange and the potential use of C5aR1 inhibitors in AAV, focusing largely on induction therapy.